Binimetinib ( Mektovi; ARRY438162; ARRY162; MEK162)

Description: Binimetinib (trade name: Mektovi; formerly ARRY-438162; ARRY-162; MEK-162) is a highly selective and orally bioavailable MEK1/2 (mitogen-activated protein kinase kinase) inhibitor with potential antineoplastic activity. It inhibits MEK1/2 with an IC50 of 12 nM in a cell-free assay. As of June 2018, binimetinib was approved by the US FDA for the treatment of unresectable or metastatic melanoma.

References: Annual Reports in Medicinal Chemistry, 2007, 42, 265–278; J Clin Invest. 2013 Jun; 123(6):2551-63.

MEK162; ARRY 162; ARRY438162; ARRY-162, ARRY-438162; MEK 162; MEK-162; ARRY162; ARRY-162; ARRY-438162; Binimetinib; Brand name: Mektovi.

Chemical Name: 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide.

InChi Key: ACWZRVQXLIRSDF-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3, 6-8, 22, 25H, 4-5H2, 1H3, (H, 23, 26)

SMILES Code: O=C(C1=C(NC2=CC=C(Br)C=C2F)C(F)=C3N=CN(C)C3=C1)NOCCO